These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1289 related articles for article (PubMed ID: 22805291)

  • 21. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
    Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
    Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C
    Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
    Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
    Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
    Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
    Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
    Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
    Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U
    Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
    Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
    Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
    Lorusso PM; Adjei AA; Varterasian M; Gadgeel S; Reid J; Mitchell DY; Hanson L; DeLuca P; Bruzek L; Piens J; Asbury P; Van Becelaere K; Herrera R; Sebolt-Leopold J; Meyer MB
    J Clin Oncol; 2005 Aug; 23(23):5281-93. PubMed ID: 16009947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
    J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
    Bendell JC; Javle M; Bekaii-Saab TS; Finn RS; Wainberg ZA; Laheru DA; Weekes CD; Tan BR; Khan GN; Zalupski MM; Infante JR; Jones S; Papadopoulos KP; Tolcher AW; Chavira RE; Christy-Bittel JL; Barrett E; Patnaik A
    Br J Cancer; 2017 Feb; 116(5):575-583. PubMed ID: 28152546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
    Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
    Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
    Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.